EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors

Shanshan Jiang, Yuyang Wang, Xiaona Fu, Jie Lou, Bingxin Gong, Weiwei Liu, Yi Li, Yuxin Sun, Chunfeng Liu, Zifang Song, Guofeng Zhou iD

Therapeutic Advances in Medical Oncology · 2025-09 · 17

DOI: 10.1177/17588359251386801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 23.10.2025. Verfasst von Shanshan Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Key Research and Development Program of China, the Noncommunicable Chronic DiseasesNational Science and Technology Major Project, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are classical tumor markers in clinical practice. However, the relationship between tumor markers and prognosis in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitor (ICI) therapy remains unclear.

Objectives

This study aims to explore the prognostic value of AFP and PIVKA-II in HCC patients treated with ICIs.

Design

This study was a single-center, retrospective investigation aimed to assess the prognostic value of AFP and PIVKA-II in HCC patients receiving immune checkpoint inhibitors.

Methods

This retrospective study included HCC patients who received ICIs treatment at Wuhan Union Hospital between July 2020 and March 2024. Serum AFP and PIVKA-II levels were collected before treatment. Patients were stratified into two groups based on AFP ⩾ 400 μg/L (yes = 1, no = 0) and PIVKA-II ⩾ 40 mAU/mL (yes = 1, no = 0). A total of 61% (114/186) of patients scored ⩽ 1, while 39% (72/186) scored 2. The objective response rate (ORR) and disease control rate (DCR) were calculated for both groups. Kaplan–Meier survival curves and Cox regression models were used to analyze overall survival (OS) and progression-free survival (PFS). Receiver operating characteristic curves were generated to demonstrate the predictive ability of combined independent prognostic factors for long-term survival.

Results

The cohort consisted of 186 patients, divided into the low-risk group ( n = 114) and the high-risk group ( n = 72). Among all patients, 34.4% (64/186) achieved complete or partial response. Concurrent elevation of AFP and PIVKA-II was inversely associated with ORR ( p = 0.012). The high-risk group exhibited significantly shorter OS (adjusted HR: 2.226 (95% CI: 1.410–3.513); p < 0.001) compared to the low-risk group. The integrated model combining AFP, PIVKA-II, and Barcelona Clinic liver cancer stage demonstrated moderate to good predictive capability for long-term risk stratification, with time-dependent area under the curves of 0.78 (9-month), 0.68 (12-month), and 0.63 (15-month).

Conclusion

Concurrent elevation of AFP and PIVKA-II is significantly associated with shorter survival outcomes in HCC patients following ICI therapy.

Schlagwörter

Stichwörter der Autor:innen

alpha fetoprotein (AFP)hepatocellular carcinomaimmunotherapyprognosisprotein induced by vitamin K absence or antagonist-II (PIVKA-II)

Autor:innen und Institutionen

  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, China.
  • Department of Pulmonary and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, No. 1063 Jiefang Avenue, Wuhan 430030, China.
  • Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, China.
  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, China.

ORCID-Profile: Guofeng Zhou

Förderung

  • the National Key Research and Development Program of China
  • the Noncommunicable Chronic DiseasesNational Science and Technology Major Project
  • the National Natural Science Foundation of China
  • the Major Special Project for Technology Innovation of Hubei Province

Zitieren

APA

Jiang, S., Wang, Y., Fu, X., Lou, J., Gong, B., Liu, W., Li, Y., Sun, Y., Liu, C., Song, Z., & Zhou, G. (2025). Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251386801

Vancouver

Jiang S, Wang Y, Fu X, Lou J, Gong B, Liu W, et al. Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251386801

BibTeX
@article{Jiang2025,
  author = {Jiang, Shanshan and Wang, Yuyang and Fu, Xiaona and Lou, Jie and Gong, Bingxin and Liu, Weiwei and Li, Yi and Sun, Yuxin and Liu, Chunfeng and Song, Zifang and Zhou, Guofeng},
  title = {Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359251386801}
}
Kostenlos starten →